Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Geoff Meacham | Citigroup | 11 questions · 0% challenging |
| Salveen Richter | Goldman Sachs | 9 questions · 0% challenging |
| Tazeen Ahmad | Bank of America | 9 questions · 0% challenging |
| Jessica Fye | JPMorgan | 9 questions · 0% challenging |
| Dave Risinger | Leerink Partners | 8 questions · 13% challenging |
| Mike Yee | UBS | 7 questions · 29% challenging |
| Evan Seigerman | BMO Capital Markets | 7 questions · 0% challenging |
| Terence Flynn | Morgan Stanley | 6 questions · 0% challenging |
| Phil Nadeau | TD Cowen | 5 questions · 20% challenging |
| William Pickering | Bernstein | 5 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Citigroup | 1 analyst | 11 questions · 0% challenging |
| Barclays | 3 analysts | 9 questions · 0% challenging |
| Bank of America | 1 analyst | 9 questions · 0% challenging |
| Goldman Sachs | 1 analyst | 9 questions · 0% challenging |
| JPMorgan | 1 analyst | 9 questions · 0% challenging |
| Leerink Partners | 1 analyst | 8 questions · 13% challenging |
| UBS | 1 analyst | 7 questions · 29% challenging |
| BMO Capital Markets | 1 analyst | 7 questions · 0% challenging |
No 8-K events recorded for this window.
Vertex posted Q1 product revenue of $2.99B, up 8%, with non-GAAP EPS of $4.47 as the CF franchise delivered steady 6% global growth and new product launches contributed 25% of total growth. FY2026 revenue guidance of $12.95-$13.1B was reiterated with all expense and tax guidance unchanged, and povetacicept IgAN Phase III interim results were described as sparkling. VX-522 mRNA therapy was discontinued, but the renal franchise rapidly expanded with multiple pipeline programs, and disciplined expense management supported margin improvement.
Innovation & R&D | Product Launch | Competitive Dynamics | Regulation Policy | Revenue Growth | Demand | Margin | Pricing | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 4 | 10 | 3 | 5 | 3 | 3 | 1 | |
| 2025Q1 | 3 | 9 | 2 | 2 | 2 | 4 | 1 | |
| 2025Q2 | 6 | 7 | 1 | 3 | 1 | |||
| 2025Q3 | 5 | 4 | 4 | 2 | 1 | |||
| 2025Q4 | 7 | 4 | 4 | 2 | 1 | |||
| 2026Q1 | 12 | 3 | 4 | 2 | 2 | 2 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Innovation & R&D | 4 | 3 | 6 | 5 | 7 | 12 |
| Product Launch | 10 | 9 | 7 | 4 | 4 | 3 |
| Competitive Dynamics | 3 | 2 | 1 | 4 | 4 | 4 |
| Regulation Policy | 5 | 2 | 3 | 2 | ||
| Revenue Growth | 3 | 2 | 2 | 2 | ||
| Demand | 3 | 4 | 2 | |||
| Margin | 1 | 1 | 1 | 1 | ||
| Pricing | 1 | 2 |
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $2.91B | +15.7% | $3.50 | -5.7% | 35.2% | 31.4% | $492M |
| FY2025 Q1 | $2.77B | +3.1% | $2.49 | -40.9% | 22.7% | 23.3% | $778M |
| FY2025 Q2 | $2.96B | +12.1% | $3.99 | +128.7% | 38.8% | 34.8% | $927M |
| FY2025 Q3 | $3.08B | +11.0% | $4.20 | +4.7% | 38.6% | 35.2% | $1.14B |
| FY2025 Q4 | $3.23B | +10.8% | $4.65 | +32.9% | 40.3% | 36.9% | $349M |
| FY2026 Q1Selected | $2.99B | +7.8% | $4.02 | +61.4% | 38.1% | 34.5% | $1.29B |
| FY2026 Q2 | $3.33B | +12.5% | $4.31 | +8.0% | 37.4% | 33.0% | $1.01B |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Calendar quarter Q1 2026Earnings call May 4, 2026
FY2026 Q1 in brief
Vertex posted Q1 product revenue of $2.99B, up 8%, with non-GAAP EPS of $4.47 as the CF franchise delivered steady 6% global growth and new product launches contributed 25% of total growth.
Newest quarter FY2026 Q2 is part of Pro · see what Pro adds →
GAAP revenue YoY +7.82% → base 6. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
Sources. Tellvest earnings-call sentiment score for Vertex Pharmaceuticals (VRTX), FY2026 Q1: 6/10. Scores: Vertex Pharmaceuticals’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: VRTX daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
What VRTX and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“you've got a lot of companies out there that are recruiting in nephrology. I mean, Vertex is, Vera is just to name a few”
Biogen names Vertex among the companies now recruiting in nephrology, signaling intensifying competition for patients/trials in the space Biogen is entering with felzartamab.
“versus, say, Otsuka, which I think is presenting their eGFR 9-month data next month and then their 2-year data coming up”
An analyst framed Otsuka as a competitor to Vertex's povitacicept in IgAN, noting Otsuka's upcoming eGFR 9-month and 2-year readouts on its competing therapy.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
VRTX Vertex Pharmaceuticals | 6 | +7.8% | |
| ALNY Alnylam Pharmaceuticals | 9 | +96.4% | |
| INCY Incyte | 9 | +20.9% | |
| INSM Insmed Incorporated | 8 | +229.6% | |
| MRNA Moderna | 8 | +263.6% | |
| REGN Regeneron Pharmaceuticals | 7 | +19.0% | |
| TECH Bio-Techne | Newest quarter — available with Pro | Newest quarter — available with Pro |
Newest-quarter details for 1 peer (score, revenue, headline, themes and macro signals) are available with Pro.